openPR Logo
Press release

Global Dendritic Cell Cancer Vaccine Market & Dendritic Cell Cancer Vaccine Clinical Trials Outlook 2023

07-07-2017 09:06 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Dendritic Cell Cancer Vaccine Market & Dendritic Cell

Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community which only eased out with the further ongoing clinical trials.

However, gone are the gloomy days for the dendritic cells, the sentinels of the immune system, as its market share in cancer market is rising exponentially. Dendritic cell cancer vaccines which started its journey with ex-vivo clinical trials in murine models have now gone on to rephrasing the molecular mechanism of the immune system, enriching our immunological knowledge and empowering our ability to counteract the tumor growth. Dendritic cells have also been successful in generating therapeutic and prophylactic options not just for cancer treatments but also for other ailments, deemed incurable.

Dendritic cells play a critical role in immune modulation, which makes them a perfect target for the clinical studies revolving around T cell induced immune reaction like allergic reaction studies, host vs graft disease, infection resistance studies and immune-compromised patient studies, besides cancer vaccines development. However, it has been seen that many tumor antigens do not induce T cell mediated immune response which could be due the absence of functional dendritic cells in the tumors. It has been observed that dendritic cells that invade colon and skin cancer cells, sometimes lack CD80 and CD86 epitopes, therefore have limited T-cell stimulatory activity. Besides, tumors are capable of secreting growth factors like interleukin-10, Tumor Growth Factor, which retards the development and the maturation stages of dendritic cells. This implies that with increased dendritic cells invading the tumor cells the probability of enhanced prognosis is greatly increased.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-and-clinical-trials-outlook-2023.php

Report Table of Contents

1. Advent of Dendritic Vaccine in Oncology

2. Cataloging towards Dendritic Cells

3. Dendritic Cells Mechanizing Immune Response
3.1 Antigen Appearance Leads to Cellular Immune Responses
3.2 Stacking of Distinct Antigens over Dendritic Cells
3.3 Dendritic Cells Source and Subsets
3.4 Trail towards Maturation
3.5 Stimulation Initiates Maturation
3.6 Migration to Lymph Node
3.7 Precision of Dendritic Cells Vaccination
3.8 Illustrations of Clinical Results among Varied Cancer
3.9 Quality Control
3.10 Immune Monitoring

4. Equipping Dendritic Cell Vaccines
4.1 Cross Presentation of CD4 T-CD8 T Cells
4.2 Strategies to Recruit, Mature and Load Dendritic Cells In Situ
4.3 Strategies to Activate NKT Cells

5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens
5.1 Dendritic Cell Cancer Vaccine and Monoclonal Antibodies
5.2 Dendritic Cell Cancer Vaccine and Peptide Based Cancer Vaccine
5.3 Dendritic Cell Cancer Vaccine and Cytokine Based Cancer Vaccine
5.4 Dendritic Cell Cancer Vaccine and Antibody Drug Conjugate Based Cancer Vaccine

6. Dendritic Cell Cancer Vaccine Market and Clinical Insight
6.1 Some Trends Involving Dendritic Cells Cancer Vaccination
6.2 Dendritic Cell Cancer Vaccine Pipeline Overview

7. Undercurrents of Dendritic Cancer Vaccine Growth

8. Challenging Milieu for Dendritic Cancer Vaccine

9. Prospective Trajectories for Future

10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication and Phase
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase II/III
10.8 Phase III

11. Marketed Dendritic Cell Vaccines Clinical Insight
11.1 Sipuleucel-T (Provenge)
11.2 Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC and CreaVax-RCC)
11.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

12. Competitve Landscape
12.1 3M Company
12.2 Activartis
12.3 Argos Therapeutics
12.4 Batavia Bioservices
12.5 Bellicum Pharmaceuticals
12.6 Creagene
12.7 DanDrit Biotech
12.8 DCPrime
12.9 Dendreon Corporation
12.10 Elios Therapeutics
12.11 ImmunoCellular Therapeutics
12.12 Immunicum
12.13 Kiromic
12.14 Medigene
12.15 Merck
12.16 Northwest Biotherapeutics
12.17 Glaxo Smith Kline
12.18 ImmunoCellular Therapeutics
12.19 SOTIO
12.20 Tella Incorporation
12.21 Theravectys
12.22 Vaxil BioTherapeutics

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Dendritic Cell Cancer Vaccine Market & Dendritic Cell Cancer Vaccine Clinical Trials Outlook 2023 here

News-ID: 613396 • Views: 272

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Dendritic

Global Dendritic Cell Cancer Vaccine Market Outlook 2020 Report
“Global Dendritic Cell Cancer Vaccine Market Outlook 2020” Report highlights: * Introduction & Mechanism of Action of Dendritic Cells * New Vaccine Strategies That Exploit Dendritic Cells Biochemistry * Dendritic Cell Cancer Vaccine Market & Clinical Insight * Comparative Insight of Dendritic Cell Vaccines & Other Class of Vaccines * Dendritic Cell Cancer Vaccine Pipeline by Country, Company, Indication & Phase * Dendritic Cell Cancer Vaccine Clinical Pipeline: 58 Vaccines * Majority in Phase I/II
Download Global Dendritic Cell Cancer Vaccine Market Outlook 2020 Report
Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community
Download Dendritic Cell Cancer Vaccine Market & Clinical Trials Insight Report
Cancer is a disease caused by the uncontrolled division of the normal body cell, when these cells lose their property of contact inhibition or the ability to know when to stop dividing, they become cancerous. A vaccine generally aims at activating the immune cells to fight against a particular antigen. This specificity of the vaccination to target and kill the infected cells is responsible for its healing property. However the
Dendritic Cell Cancer Vaccine Market Dendritic Cell Cancer Vaccine Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Advent of Dendritic Vaccine in Oncology 2. Cataloging towards Dendritic Cells 3. Dendritic Cells Mechanizing Immune Response 3.1 Antigen Appearance Leads to Cellular Immune Responses 3.2 Stacking of Distinct Antigens over Dendritic Cells 3.3 Dendritic Cells Source and Subsets 3.4 Trail towards Maturation 3.5 Stimulation Initiates Maturation 3.6 Migration to Lymph Node 3.7
Dendritic Cell Cancer Vaccine Market & Clinical Insight
Dendritic cells are branched cells found in lymphoid organs and they are responsible for antigen display and T-cell activation. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. In 1868, Paul Langerhans discovered dendritic cells and thought that they are part of nervous system because of their branched structure. Until 1973 their identity was mistaken, Ralph Steinman and Zanvil Cohn identified them
Global Dendritic Cell Cancer Vaccine Market Outlook 2020
Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community